News from camurus ab A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

16 Jul, 2019, 07:19 BST Ra Pharmaceuticals and Camurus Announce Exclusive License Agreement for FluidCrystal® Extended Release Formulation of Zilucoplan

Ra Pharmaceuticals, Inc. (Nasdaq: RARX) and Camurus AB (Nasdaq STO: CAMX) today announced an exclusive worldwide license agreement for the use of...


20 Jun, 2019, 12:17 BST Camurus Receives IND Acceptance From the FDA to Enter Phase 3 with CAM2029 for Treatment of Acromegaly

Camurus (NASDAQ STO: CAMX), a commercial stage biopharmaceutical company specializing in long-acting medicines for severe and chronic disorders,...


04 Jun, 2019, 08:38 BST Camurus Announces Publication of Phase 3 Study Results Showing Long-term Safety, Efficacy and High Rates of Patient Satisfaction With Buvidal®

Camurus announces that the leading drug dependence journal Addiction has today published full results from a 48-week, open-label, global Phase 3...


09 May, 2019, 12:17 BST Camurus Interim Report January-March 2019

"Initial sales of Buvidal® follows plan and we are expecting to see significant growth during the year" Summary first quarter 2019 Buvidal® launched...


09 Apr, 2019, 16:59 BST Braeburn Initiates Court Proceedings to Overturn Exclusivity and Seeks Immediate Market Approval of Brixadi™ in the US

Camurus' (NASDAQ STO: CAMX) US partner, Braeburn Inc., today announced that the company today will file an action in federal district court for the...


06 Apr, 2019, 18:08 BST Positive Treatment Results for Buvidal® in Fentanyl Users Presented at the ASAM 50th Annual Conference

Camurus announces positive post-hoc analyses results from the randomized, double-blind, double-dummy Phase 3 study of CAM2038 (Buvidal®,...


06 Feb, 2019, 06:17 GMT Camurus - Full Year Report 2018

"The approval of Buvidal is a major milestone for Camurus and an important validation of our innovative FluidCrystal® technology." Business...


01 Feb, 2019, 07:10 GMT Camurus to Present Full Year 2018 Results on 6 February

Camurus (NASDAQ STO: CAMX) today announced that the Company will release its full year report on 6 February at 7:00 am CET. The report will be...


23 Dec, 2018, 14:38 GMT Camurus AB: US FDA Issues A Tentative Approval of Brixadi™ (buprenorphine) Extended-release Injection for Treatment of Opioid Use Disorder

Camurus (NASDAQ STO: CAMX) announced today that the US Food and Drug Administration (FDA) has issued Camurus' US partner Braeburn a tentative...


28 Nov, 2018, 22:45 GMT Buvidal® Weekly and Buvidal® Monthly (CAM2038) Approved in Australia as the First Long-acting Treatment of Opioid Dependence

Camurus announced today that the Australian Therapeutic Goods Administration (TGA) has approved the company's lead products Buvidal® Weekly and...


22 Nov, 2018, 11:15 GMT Camurus Receives EU Approval for Weekly and Monthly Buvidal® (CAM2038) for Opioid Dependence

Camurus announced today that the European Commission (EC) has approved weekly and monthly Buvidal® (prolonged release buprenorphine) for the...


10 Oct, 2018, 07:13 BST Camurus to Present at Jefferies 2018 London Healthcare Conference

Camurus (Nasdaq Stockholm: CAMX) today announced that that the Company will present at the Jefferies 2018 London Healthcare Conference 14 November at ...


21 Sep, 2018, 12:34 BST CHMP Recommends Approval of Buvidal® (CAM2038) for the Treatment of Opioid Dependence

Camurus (NASDAQ STO: CAMX) announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use, CHMP, has adopted a...


18 Sep, 2018, 15:26 BST Camurus Announces Positive Topline Phase 3 Results for CAM2038 in Opioid Experienced Patients With Chronic Low-back Pain

- Phase 3 study successfully meets primary and secondary endpoints, demonstrating significant relief of average and worst pain in patients on CAM2038 ...


16 Jul, 2018, 07:32 BST Camurus Announces PDUFA Date for CAM2038 for the Treatment of Opioid use Disorder

Camurus (NASDAQ STO: CAMX) announced today that the US Food and Drug Administration (FDA) assigned a Prescription Drug User Fee Act (PDUFA) goal date ...


29 Sep, 2017, 09:27 BST Camurus Announces European Medicines Agency Validation of CAM2038 Marketing Authorization Application for Treatment of Opioid Dependence

Camurus (NASDAQ STO: CAMX) today announced the company's Marketing Authorization Application (MAA) for the investigational, weekly and monthly...


18 Sep, 2017, 09:17 BST Camurus Announces That FDA Grants Priority Review of NDA for Weekly and Monthly CAM2038 Buprenorphine Depots for Treatment of Opioid Use Disorder

The FDA has assigned a PDUFA target date of January 19, 2018 Camurus (NASDAQ STO: CAMX) announces that the U.S. Food and Drug Administration (FDA)...


14 Nov, 2016, 07:00 GMT Braeburn Pharmaceuticals and Camurus Announce Positive Top-line Phase 3 Results for Long-acting Buprenorphine (CAM2038) for Treatment of Opioid Addiction

- Head-to-head Study of CAM2038 Versus Daily Sublingual Buprenorphine - CAM2038 met Both FDA and EMA Primary Endpoints of Non-inferiority (p<0.001) - ...